Side-by-side comparison of AI visibility scores, market position, and capabilities
Positive 48-week Phase 2 BEHOLD data for UBX1325 in DME published in NEJM Evidence. Single-injection senolytic durability confirmed in diabetic macular edema.
Unity Biotechnology is the most clinically advanced senolytic drug company, with its UBX1325 program delivering long-lasting vision improvements in diabetic macular edema (DME) from a single intravitreal senolytic injection. The 48-week Phase 2 BEHOLD trial data published in NEJM Evidence (one of the highest-impact medical journals) confirmed durable efficacy — maintained vision improvement with a single injection over nearly a year — validating the senolytic hypothesis in human ocular disease.
Aleph Alpha raised €500M+ and pivoted to sovereign AI solutions for European governments, positioning as the leading provider of GDPR-compliant, EU-hosted AI infrastructure for regulated industries.
Aleph Alpha is a German AI company building sovereign AI infrastructure for European governments and enterprises that require data sovereignty, GDPR compliance, and AI hosted within EU borders. Its Pharia AI platform provides LLM capabilities deployed on-premises or in EU data centers, serving German federal ministries, European defense agencies, and regulated industries including banking, healthcare, and legal services.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.